Edwards Lifesciences Co. (NYSE:EW) Shares Bought by GAMMA Investing LLC

GAMMA Investing LLC boosted its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 7,061.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 340,946 shares of the medical research company's stock after purchasing an additional 336,185 shares during the quarter. GAMMA Investing LLC owned about 0.06% of Edwards Lifesciences worth $24,712,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Crowley Wealth Management Inc. bought a new stake in Edwards Lifesciences in the fourth quarter worth $26,000. Vega Investment Solutions purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth $27,000. Millstone Evans Group LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $30,000. Finally, Park Square Financial Group LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $44,000. Institutional investors own 79.46% of the company's stock.

Analysts Set New Price Targets

EW has been the subject of several recent research reports. Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a research report on Monday. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Wall Street Zen cut Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday, May 16th. Barclays increased their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Finally, Citigroup restated a "buy" rating and issued a $95.00 price target (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $80.20.

Insider Activity

In related news, VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.48, for a total transaction of $27,792.00. Following the transaction, the vice president now directly owns 22,588 shares of the company's stock, valued at $1,569,414.24. This trade represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the transaction, the chief executive officer now owns 59,083 shares in the company, valued at $4,106,859.33. This represents a 9.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 59,012 shares of company stock worth $4,224,717. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Trading Down 0.3%

EW stock traded down $0.21 during mid-day trading on Friday, reaching $77.56. The company had a trading volume of 2,633,909 shares, compared to its average volume of 5,193,909. The company has a market capitalization of $45.50 billion, a PE ratio of 11.13, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The firm has a 50 day moving average of $73.87 and a 200 day moving average of $72.69. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. The company had revenue of $1.41 billion for the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Edwards Lifesciences's revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.66 earnings per share. On average, equities analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.